Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

IMpower-150: EGFR-Mutated Subset Analysis

November 20th 2018

The Role of Immunotherapy in Squamous NSCLC

November 20th 2018

First-Line Treatment Recommendations Based on TMB

November 20th 2018

PD-1 Inhibitors in NSCLC: Combination or Monotherapy

November 20th 2018

Dr. Perez-Soler on Current Status of Biomarkers in SCLC

November 20th 2018

Roman Perez-Soler, MD, chairman of the Department of Oncology and chief of the Division of Medical Oncology at Montefiore Medical Center, discusses the current status of biomarkers of small cell lung cancer.

Thoracic Oncologist Highlights Recent Pembrolizumab Data in NSCLC

November 19th 2018

Pembrolizumab (Keytruda) has emerged as an effective frontline treatment option for select patients with metastatic non–small cell lung cancer, showing an overall survival advantage across 3 phase III clinical trials.

Dr. Haigentz on the Potential of Erlotinib and Bevacizumab in EGFR-Mutant NSCLC

November 17th 2018

Missak Haigentz, MD, chief of Hematology and Oncology at Morristown Medical Center and medical director of Atlantic Hematology and Oncology for Atlantic Medical Group at the Carol G. Simon Cancer Center, discusses the potential of erlotinib (Tarceva) and bevacizumab (Avastin) in EGFR-mutant non–small cell lung cancer (NSCLC).

Durvalumab Combo Misses OS Endpoint in Frontline Metastatic NSCLC

November 16th 2018

The frontline combination of durvalumab (Imfinzi) and tremelimumab did not induce a statistically significant improvement in overall survival compared to standard chemotherapy in patients with metastatic non–small cell lung cancer.

Treatment Options for Lung Cancer Mutations & Contingencies

November 16th 2018

Immunotherapy Options for Lung Cancer Variations

November 16th 2018

The Current State of Advanced NSCLC Treatment & Contingencies

November 16th 2018

I-O as First-Line Therapy for Driver-Mutated NSCLC

November 16th 2018

RET-Fusion NSCLC Treatments LOXO-292 & BLU-667

November 16th 2018

HER2- and MET-Mutation/Amplification Therapies

November 16th 2018

Treatment Options for ALK/ROS1 Mutation

November 16th 2018

First-Line Shifts in Driver-Mutation Subsets According to FLAURA

November 16th 2018

Pembrolizumab Treatment in Stage III NSCLC and Alternatives

November 16th 2018

Surgery Options for NSCLC & I-O Therapy in EGFR-Mutations

November 16th 2018

I-O Options for Stage III NSCLC & International PD-L1 Restrictions

November 16th 2018

Post-Immunotherapy & Frontline Treatments for Advanced NSCLC

November 16th 2018